David Hallett

Wyeth LLC develops, manufactures, and distributes pharmaceuticals and biological substances. The company was founded in 1926 and is headquartered in Madison, NJ.

The Wellcome Trust Ltd. engages welfare and charitable services. It supports the discovery of vaccines and drug-resistant infections, diversity and inclusion, open research, government investment in research, data sharing in public health emergencies, and strengthening ecosystems. The company was founded by Henry Wellcome in 1936 and is headquartered in London, UK.

Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ.

Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Dana-Farber Cancer Institute, Inc. provides treatment to cancer patients and also researches new cancer diagnostics, treatments, and preventions. The firm's patients receive treatment through its cancer centers operated with Brigham and Women's Hospital, Children's Hospital Boston, Massachusetts General Hospital, and Beth Israel Deaconess Medical Center. The company was founded by Sidney Farber in 1947 and is headquartered in Boston, MA.

Arm Ltd. engages in the licensing, marketing, and research and development of microprocessors, system intellectual property (IP), graphics processors, physical IP and associated systems IP, software and tools. Its products include Pelion IoT platform, Mbed OS, IoT SoC, and Kigen SIM. The company was founded by Michael Peter Muller in November 1990 and is headquartered in Cambridge, the United Kingdom.

Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis.

Part of Georg Thieme Verlag KG, Thieme Medical Publishers, Inc. is an American company committed to improving health and healthcare. The private company is based in New York. The company achieves this by providing key information at the right time and in the right place.

Novo Principal Investments (Novo Principal) is a private equity operating division of Novo Nordisk Fonden. The firm was established in 1999, and is headquartered in Hellerup, Denmark.

Cambridge Network Ltd. operates as a membership organization. It bring people together to meet each other and share ideas, encouraging collaboration and partnership for shared success. The company was founded by Alec Broers, Hermann Hauser, David Cleevely, Nigel Brown, Fred Hallsworth, and Anthony Ross in 1998 and is headquartered in Cambridge, the United Kingdom.

Part of Moelis & Co., Moelis & Co. (UK) LLP is an independent investment bank that provides confidential and unconflicted strategic advice to clients across various industries. The private company is based in London, UK. Leveraging their extensive network of 21 geographic locations, the British company delivers the best solutions to their clients. Mark Jonathan Aedy has been the CEO of the company since 2010.

UK Biobank Ltd. is a biomedical database and research resource that contains genetic, lifestyle, and health information from half a million participants aged between 40-69 years in 2006-2010 from across the UK. The organization has over 220 dedicated members of staff, based in multiple locations across the UK. UK Biobank's research resource is a major contributor to the advancement of modern medicine and treatment, enabling better understanding of the prevention, diagnosis, and treatment of a wide range of serious and life-threatening illnesses, including cancer, heart diseases, and stroke. The non-profit company is based in Stockport, UK, and has subsidiaries in the United Kingdom. The database includes blood samples, heart and brain scans, and genetic data that are accessible to approved researchers who are undertaking health-related research that is in the public interest. The CEO of the British company is Rory Collins.

Shanghai Yunfeng Investment Management Co. Ltd (Yunfeng Capital) is a private equity firm founded in 2010 by Feng Yu and Yun Ma. The firm is headquartered in Shanghai, China.

Integrated Clinical Oncology Network Pty Ltd. engages in the provision of cancer and hematological care services. It offers chemotherapy compunding, pharmacy management, remote radiation therapy planning, and medical physics services. The firm also offers patients the option of emerging treatment through clinical trials. The company was founded by Stuart Giles in 2012 and is headquartered in South Brisbane, Australia.

Pear Therapeutics (US), Inc. develops and provides a platform that combines pharmaceutical preparations with scientifically validated software applications. It offers eFormulation, pharmaceutical-software combination products. The firm combines digital therapies with supplements, medical foods and pharmaceuticals to create more effective treatment solutions. The company was founded in 2013 by Corey M. McCann, Stephen Kennedy Smith and William Greene and is headquartered in Boston. MA.

Tempus Labs, Inc. enagegs in the development of a platform that analyzes clinical and molecular data points focusing on cancer research. It connects physicians treatment options and relevant insights for patients based on their unique molecular profile and analytics and machine-learning algorithms. The firm offers genomic sequencing, clinical data structuring, image recognition, biological modeling, and time trial program. The company was founded by Bradley A. Keywell and Eric P. Lefkofsky in 2015 and is headquartered in Chicago, IL.

Mission Bio, Inc. engages in the provision of tools for the study of cellular heterogeneity in human health and life science research. It develops research tools that allow high-throughput, single-cell nucleic acid characterization across a variety of research applications, including oncology and immunology. The company was founded by Charlie Silver, Adam Sciambi, Adam Abate, and Dennis Eastburn on June 29, 2011 and is headquartered in San Francisco, CA.

Aetion, Inc. provides data analytics software solutions. The firm?s Aetion Evidence Platform enables life sciences customers to transform disparate data sets into evidence needed to make critical business decisions; and helps payers determine effective treatments for specific patient populations and measure impact in outcomes and utilization. The company was founded by Jeremy A. Rassen, Sebastian Schneeweiss and Allon Rauer in 2013 and is headquartered in New York, NY.

Exscientia AI Ltd. is an artificial intelligence (AI) driven pharmatech company, which develops bi-specific small molecule immuno-oncology therapeutics. The firm offers phenotypic drug design and selective single target molecules. The company was founded by Andrew Lee Hopkins in July 2012 and is headquartered in Oxford, the United Kingdom.

Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.

Ohana Biosciences, Inc. operates early stage biotechnology firm. The company is headquartered in Cambridge, MA.

Owkin, Inc. operates as an artificial intelligence company. It develops software which allow prediction modeling and population comparison services. The firm's products include OWKIN Socrates and OWKIN Services. The company was founded by Thomas Clozel and Gilles Wainrib in 2016 and is headquartered in Albany, NY.

Kinetic Discovery Ltd. engages in the provision of drug discovery services. It offers full kinetic characterization, compound screening, fragment based screening, membrane protein analysis, active concentration determination, epitope mapping, promiscuous binding identification, and consultancy and assay development. The company was founded by Iva Navratilova and Andrew L. Hopkins and is headquartered in Dundee, the United Kingdom.

Harbinger Health, Inc. is a company based in Cambridge, MA. Harbinger Health is pioneering the detection of early cancer and enabling foundationally new approaches to cancer screening, diagnosis, and management. The company combines advances in artificial intelligence with proprietary insights into the biology of the beginnings of cancer to identify cancer before it is visible or symptomatic with the aim of developing a low-cost, multi-cancer blood test. Harbinger envisions a future where cancer could be kept from forming, making a cancer diagnosis a routine health problem to be addressed rather than a life-altering event to be feared with profound implications for people, healthcare systems, and societies. The company fundamentally transforms cancer care for everyone. The company was founded in 2020 by Alexander Meissner, Sidney Farber, Zachary Smith, Franziska Michor. The CEO is Stephen Hahn.